{"analyses":[{"ciLowerLimit":"-4.877","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.685","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"2.439","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.97","paramType":"Slope","paramValue":"-0.096","statisticalComment":"The treatment effect was determined by testing the significance of the group by time interaction in GEE using a one degree-of-freedom (df) test.","statisticalMethod":"Generalized Estimating Equation (GEE)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.726","value":"26.608"},{"groupId":"OG001","spread":"1.089","value":"25.773"}]}],"title":"BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.293","value":"24.068"},{"groupId":"OG001","spread":"1.252","value":"26.342"}]}],"title":"6m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.423","value":"25.426"},{"groupId":"OG001","spread":"1.432","value":"27.014"}]}],"title":"12m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.637","value":"24.375"},{"groupId":"OG001","spread":"2.665","value":"28.411"}]}],"title":"18m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.488","value":"24.561"},{"groupId":"OG001","spread":"1.509","value":"27.038"}]}],"title":"24m"}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"A liver function measurement (in U/L). Normal range is 14-20 for men, 10-36 for women. The mean is reported by arm at each timepoint with corresponding standard errors.","dispersionType":"Standard Error","groups":[{"description":"Patients received Carvedilol PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG000","title":"Arm I (Carvedilol)"},{"description":"Patients received Placebo PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG001","title":"Arm II (Placebo)"}],"paramType":"MEAN","populationDescription":"We excluded 31 participants who did not have a second time point assessment of echocardiography, resulting in 151 analyzable participants.","reportingStatus":"POSTED","timeFrame":"Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation","title":"Average Aspartate Aminotransferase","type":"SECONDARY","unitOfMeasure":"IU/L"}